KEYC - OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Wh

OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In OHR Pharmaceutical, Inc. To Contact The Firm

Posted: Updated:


Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OHR Pharmaceutical, Inc. (“OHR” or the “Company”) (NASDAQ:OHRP).

On January 4, 2018, OHR issued a press release announcing negative results from its study evaluating the safety and efficacy of Squalamine, the Company’s leading therapeutic candidate for improving vision outcomes in patients suffering from ophthalmic diseases. Specifically, patients receiving the Squalamine combination therapy failed to show vision improvement over candidates receiving only a Lucentis monotherapy.

On this news, OHR’s share price declined significantly, causing harm to investors.

If you invested in OHR stock or options and would like to discuss your legal rights, click There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll freeat 877-247-4292 or at 212-983-9330 or by sending an e-mail

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330

Copyright Business Wire 2018

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal requests please contact